Clene (NASDAQ:CLNN) Major Shareholder Chidozie Ugwumba Sells 4,138 Shares

Clene Inc. (NASDAQ:CLNN) major shareholder Chidozie Ugwumba sold 4,138 shares of the business’s stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $6.03, for a total value of $24,952.14. Following the completion of the sale, the insider owned 783,590 shares in the company, valued at $4,725,047.70. The trade was a 0.53% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Chidozie Ugwumba also recently made the following trade(s):

• On Monday, December 29th, Chidozie Ugwumba sold 8,096 shares of Clene stock. The stock was sold at an average price of $5.95, for a total transaction of $48,171.20.
• On Tuesday, December 23rd, Chidozie Ugwumba sold 6,831 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $42,830.37.
• On Friday, December 26th, Chidozie Ugwumba sold 3,350 shares of Clene stock. The stock was sold at an average price of $6.32, for a total transaction of $21,172.00.
• On Wednesday, December 24th, Chidozie Ugwumba sold 1,490 shares of Clene stock. The shares were sold at an average price of $6.27, for a total transaction of $9,342.30.
• On Monday, December 22nd, Chidozie Ugwumba sold 4,367 shares of Clene stock. The shares were sold at an average price of $6.54, for a total transaction of $28,560.18.
• On Friday, December 19th, Chidozie Ugwumba sold 5,582 shares of Clene stock. The stock was sold at an average price of $6.45, for a total transaction of $36,003.90.
• On Wednesday, December 3rd, Chidozie Ugwumba sold 56,577 shares of Clene stock. The shares were sold at an average price of $7.86, for a total value of $444,695.22.
• On Thursday, December 18th, Chidozie Ugwumba sold 5,816 shares of Clene stock. The stock was sold at an average price of $6.33, for a total value of $36,815.28.
• On Wednesday, December 17th, Chidozie Ugwumba sold 2,884 shares of Clene stock. The stock was sold at an average price of $6.61, for a total value of $19,063.24.
• On Tuesday, December 16th, Chidozie Ugwumba sold 7,030 shares of Clene stock. The shares were sold at an average price of $6.31, for a total value of $44,359.30.

Clene Stock Down 0.4%

Shares of NASDAQ:CLNN traded down $0.03 during midday trading on Wednesday, hitting $5.94. The stock had a trading volume of 44,239 shares, compared to its average volume of 106,335. The business’s 50-day simple moving average is $8.20 and its 200-day simple moving average is $6.34. Clene Inc. has a 12 month low of $2.28 and a 12 month high of $13.50. The company has a market cap of $61.33 million, a P/E ratio of -1.75 and a beta of 0.79.

Clene (NASDAQ:CLNN) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.85) EPS for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.25). The firm had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.06 million. As a group, equities analysts predict that Clene Inc. will post -5.19 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have issued reports on CLNN shares. D. Boral Capital reaffirmed a “buy” rating and set a $23.00 price target on shares of Clene in a report on Wednesday, December 10th. UBS Group restated a “buy” rating on shares of Clene in a research report on Wednesday, December 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Clene in a research report on Tuesday, October 14th. Finally, Benchmark reissued a “buy” rating on shares of Clene in a report on Thursday, December 4th. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $32.60.

Institutional Investors Weigh In On Clene

Several hedge funds have recently modified their holdings of CLNN. Scoggin Management LP increased its stake in shares of Clene by 75.1% in the 3rd quarter. Scoggin Management LP now owns 250,000 shares of the company’s stock valued at $1,506,000 after acquiring an additional 107,250 shares in the last quarter. Lunt Capital Management Inc. raised its holdings in shares of Clene by 71.2% during the second quarter. Lunt Capital Management Inc. now owns 51,010 shares of the company’s stock valued at $199,000 after purchasing an additional 21,217 shares during the period. Jane Street Group LLC bought a new position in shares of Clene during the 2nd quarter worth about $47,000. Finally, Jones Financial Companies Lllp acquired a new stake in shares of Clene in the 3rd quarter valued at about $29,000. Institutional investors and hedge funds own 23.28% of the company’s stock.

Clene Company Profile

Clene (NASDAQ: CLNN), also known as Clene Nanomedicine, is a clinical-stage biopharmaceutical company developing proprietary nanoparticle therapies aimed at treating neurodegenerative and demyelinating disorders. The company’s flagship product, CNM-Au8, is a suspension of catalytic gold nanocrystals designed to enhance cellular energy metabolism, promote remyelination, and reduce oxidative stress. Clene’s platform leverages the unique physicochemical properties of its nanoparticles to support neuronal health, with a focus on diseases that currently lack effective disease-modifying treatments.

Clene’s lead candidate, CNM-Au8, is undergoing multiple clinical trials targeting conditions such as amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple sclerosis (MS).